NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.
The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.
However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.